Cindy Rose, Microsoft's chief operating officer for global enterprise sales, is leaving the tech behemoth to become CEO ...

Absci Corporation (NASDAQ:ABSI) is a Washington-headquartered data-first generative AI drug creation company that perfectly ...

Absci also continues to focus its investments and operations on strategic initiatives and near-term inflection points, providing cash and cash equivalents and short-term investments into late 2025 ...

Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Learn more about ABSI stock here.

Absci gained on animal testing phaseout news, but the change has limited near-term impact on its investment case. Read why ABSI stock is a hold.

We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Absci Corporation (NASDAQ:ABSI) stands against the other ...

Absci Corporation (NASDAQ:ABSI) sells itself as an AI-integrated drug company. The stock is up significantly so far in 2025 as it announced a collaboration with AMD.

Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly ...

About Absci Corp. Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partne ...

Absci and Memorial Sloan Kettering partner to search for cancer drugs using AI The partnership combines Absci's algorithms for novel antibodies with MSK's extensive oncology research.

Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly ...